Sensei Biotherapeutics Acquires Faeth Therapeutics (PIKTOR) and Raises $200 Million in Concurrent Private Placement
February 18, 2026
Sensei Biotherapeutics, Inc. announced it acquired Faeth Therapeutics Inc., bringing Faeth’s lead all-oral multi-node oncology asset PIKTOR into Sensei’s pipeline. Concurrently, Sensei entered into a definitive agreement for a $200 million private placement (Series B non-voting convertible preferred stock) with a syndicate of life sciences investors to fund key clinical milestones in endometrial and breast cancer.
- Buyers
- Sensei Biotherapeutics, Inc.
- Targets
- Faeth Therapeutics Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Ipsen Acquires Kartos Therapeutics for Up to $1.75 Billion
June 29, 2026
Biotechnology
Ipsen entered into a definitive merger agreement to acquire clinical-stage biopharmaceutical company Kartos Therapeutics. The deal brings navtemadlin, an oral MDM2 inhibitor in Phase III for TP53 wild-type myelofibrosis, into Ipsen’s late-stage oncology pipeline, with $450 million paid upfront and up to $1.3 billion in regulatory and sales-related milestones.
-
Quince Therapeutics Acquires Orphai Therapeutics in Stock-for-Stock Deal and Raises Up to $187M Private Placement
May 19, 2026
Biotechnology
Quince Therapeutics, Inc. announced it has acquired Orphai Therapeutics Inc. in a stock-for-stock merger, bringing Orphai’s inhaled rapamycin (LAM-001) pulmonary pipeline into Quince. Concurrently, Quince entered into a definitive agreement for a private placement financing raising up to $187 million gross proceeds (including $115 million upfront), expected to fund clinical development milestones through 2028.
-
Eilean Therapeutics Acquires Ness Therapeutics
March 4, 2024
Biotechnology
Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.
-
Petauri Health (Oak Hill) Acquires The Kinetix Group
June 13, 2023
Healthcare Services
Petauri Health, a pharmaceutical commercialization platform formed by Oak Hill Capital, has acquired The Kinetix Group (TKG), a New York–based market access, access marketing, and medical affairs agency. The Kinetix founders will remain in leadership roles as TKG becomes the inaugural add-on to the Petauri platform, expanding the platform's market access, medical affairs, and real-world evidence capabilities.
-
Pasithea Therapeutics Acquires AlloMek Therapeutics
October 11, 2022
Biotechnology
Pasithea Therapeutics Corp. (Nasdaq: KTTA) acquired AlloMek Therapeutics, LLC, obtaining the preclinical MEK 1/2 inhibitor CIP-137401 to expand its CNS-focused drug-development pipeline. The deal closed on October 11, 2022 and included $1.05 million in upfront cash, issuance of restricted stock and warrants, plus potential clinical/regulatory milestones and royalties.
-
PTC Therapeutics to Acquire Censa Pharmaceuticals
May 6, 2020
Biotechnology
PTC Therapeutics has entered into an agreement to acquire Censa Pharmaceuticals to obtain CNSA-001 (sepiapterin), a Phase 3–ready oral therapy for phenylketonuria (PKU) and other BH4-pathway disorders. Under the deal PTC will pay approximately $10 million cash upfront and up to 850,000 shares of PTC common stock, plus potential development, regulatory and sales milestones totaling hundreds of millions of dollars.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.